Abstract
Introduction Improved survival prediction and risk stratification in non-small cell lung cancer (NSCLC) would lead to better prognosis counseling, adjuvant therapy selection, and clinical trial design. We propose the PHOM (persistent homology) score, the radiomic quantification of solid tumor topology, as a solution.
Methods Patients diagnosed with stage I or II NSCLC primarily treated with stereotactic body radiation therapy (SBRT) were selected (n = 554). The PHOM score was calculated on each patient’s pre-treatment CT scan (10/2008 to 11/2019). PHOM score, age, sex, stage, Karnofsky Performance Status (KPS), Charlson-Comorbidity Index (CCI), and post-SBRT chemotherapy were predictors in the Cox proportional hazards models for overall and cancer-specific survival. Patients were split into high and low PHOM score groups compared using Kaplan-Meier curves for overall survival and cumulative incidence curves for cause specific death. Finally, we generated a validated nomogram to predict overall survival, publicly available at https://eashwarsoma.shinyapps.io/LungCancerTDATest/.
Results PHOM score was a significant predictor for overall survival (HR: 1.17, 95% CI: 1.07−1.28) and was the only significant predictor for cancer-specific survival (1.31, 95% CI: 1.11−1.56) in the multivariable Cox model. The median survival for the high PHOM group was 29.2 months (95% CI: 23.6−34.3), which was significantly worse compared to the low PHOM group (45.4 months, 95% CI: 40.1−51.8, p < 0.001). The high PHOM group had a significantly greater chance of cancer-specific death at post treatment month 65 (0.244, 95%CI: 0.192−0.296) compared to the low PHOM group (0.171, 95% CI: 0.123−0.218, p = 0.029).
Conclusions The PHOM score is associated with cancer-specific survival and predictive of overall survival. Our developed nomogram can be used to inform clinical prognosis and assist in making post-SBRT treatment considerations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JGS was supported by NIH grant R37 CA244613 and American Cancer Society. ES and RRW were supported by the Case Comprehensive Cancer Center Summer Training Grant for medical students. KY was supported by the Computational Genomic Epidemiology of Cancer (CoGEC) Program at Case Comprehensive Cancer Center (T32CA094186), Young Investigator Award from ASCO Conquer Cancer Foundation, and RSNA Research Resident Grant.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Cleveland Clinic Foundation gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Email: evs27{at}case.edu
-Modified title, clarifications in methodology, new supplemental figures and excel file
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
